Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press8410.17650/2222-1468-2012-0-3-56-58ORIGINAL REPORTSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯBEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMASБЕВАЦИЗУМАБ В СОЧЕТАНИИ С ИРИНОТЕКАНОМ В ЛЕЧЕНИИ РЕЦИДИВОВ ГЛИОБЛАСТОМNaskhletashviliD. R.НасхлеташвилиД. Р.
Russian Federation
nas-david@yandex.ruGorbunovaV. A.ГорбуноваВ. А.
Russian Federation
BychkovM. B.БычковМ. Б.
Russian Federation
BekyashevA. Kh.БекяшевА. Х.
Russian Federation
KarakhanV. B.КараханВ. Б.
Russian Federation
AleshinV. A.АлешинВ. А.
Russian Federation
BelovD. M.БеловД. М.
Russian Federation
MoskvinaE. A.МосквинаЕ. А.
Russian Federation
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, МоскваГБОУ ДПО «Российская медицинская академия последипломного образования» Минздрава России, МоскваN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowОтделение опухолей черепно-челюстно-лицевой области НИИ клинической онкологии ФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, МоскваN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва150420122356581804201518042015Copyright ©; 2012, Naskhletashvili D.R., Gorbunova V.A., Bychkov M.B., Bekyashev A.K., Karakhan V.B., Aleshin V.A., Belov D.M., Moskvina E.A.Copyright ©; 2012, Насхлеташвили Д.Р., Горбунова В.А., Бычков М.Б., Бекяшев А.Х., Карахан В.Б., Алешин В.А., Белов Д.М., Москвина Е.А.2012Naskhletashvili D.R., Gorbunova V.A., Bychkov M.B., Bekyashev A.K., Karakhan V.B., Aleshin V.A., Belov D.M., Moskvina E.A.Насхлеташвили Д.Р., Горбунова В.А., Бычков М.Б., Бекяшев А.Х., Карахан В.Б., Алешин В.А., Белов Д.М., Москвина Е.А.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/84

The main tasks of the study were to evaluate the efficiency of treatment and to estimate time to progression and survival rates in patients with recurrent glioblastomas receiving combination treatment with irinotecan and bevacizumab. Five (41.7 %) patients achieved partial regression; disease stabilization and progression were observed in 5 (41.7 %) and 2 (16.6 %) cases, respectively. The median time to disease progression was 5.5 months; 6-month and one-year survival rates were 66.6 and 25 %. The median overall survival was 9.0 months. Treatment tolerability was satisfactory. Thus, the preliminary results of our study show the high efficiency of a combination therapy regimen incorporating bevacizumab and irinotecan for patients with recurrent glioblastomas and they are comparable with the data available in the literature on investigations of the efficiency of this treatment regimen. This study is being continued. 

Основные задачи исследования – оценка эффективности лечения, времени до прогрессирования и выживаемости пациентов c рецидивами глиобластом, получающих комбинированное лечение иринотеканом и бевацизумабом. У 5 (41,7 %) пациентов достигнута частичная регрессия, у 5 (41,7 %) – стабилизация болезни, в 2 (16,6 %) случаях отмечено прогрессирование болезни. Медиана времени до прогрессирования болезни составила 5,5 мес, 6-месячная выживаемость – 66,6 %, одногодичная выживаемость – 25 %. Медиана общей выживаемости пациентов составила 9,0 мес. Переносимость лечения была удовлетворительной. Таким образом, предварительные результаты нашего исследования показывают высокую эффективность схемы комбинированной терапии с включением бевацизумаба и иринотекана у больных с рецидивами глиобластом и сопоставимы с литературными данными по изучению эффективности данного режима лечения. Исследование продолжается.

glioblastomasrecurrencebevacizumabirinotecanглиобластомарецидивбевацизумабиринотекан1. Cloughesy T.F., Prados M.D., Mikkelsen T. et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) (abstract). Clin Oncol 2008;26:2010b.Cloughesy T.F., Prados M.D., Mikkelsen T. et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) (abstract). Clin Oncol 2008;26:2010b.2. Fisher J.L., Schwartzbaum J.A., Wrensch M. et al. Epidemiology of brain tumors. Neurol Clin 2007;25:867–90.Fisher J.L., Schwartzbaum J.A., Wrensch M. et al. Epidemiology of brain tumors. Neurol Clin 2007;25:867–90.3. Kreisl T.N., Kim L., Moore K. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab and irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740–5.Kreisl T.N., Kim L., Moore K. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab and irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740–5.4. Nghiemphu P.L., Liu W., Lee Y. et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72:1217–22.Nghiemphu P.L., Liu W., Lee Y. et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009;72:1217–22.5. Norden A.D., Young G.S., Setayesh K. et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779–87.Norden A.D., Young G.S., Setayesh K. et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779–87.6. Pope W.B., Lai A., Nghiemphu P. et al. Cloughesy T.E. MRI in patients with highgrade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258–60.Pope W.B., Lai A., Nghiemphu P. et al. Cloughesy T.E. MRI in patients with highgrade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258–60.7. Schmidt N.O., Westphal M., Hagel C. et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factoring human gliomas and their relation to angiogenesis. Int J Cancer 1999;84:10–8.Schmidt N.O., Westphal M., Hagel C. et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factoring human gliomas and their relation to angiogenesis. Int J Cancer 1999;84:10–8.8. Stark-Vancs V. Bevacizumab (Avastin) and CPT-11 (Camptosar) in the treatment of relapsed malignant glioma (abstract). Neurooncol 2005;7:369.Stark-Vancs V. Bevacizumab (Avastin) and CPT-11 (Camptosar) in the treatment of relapsed malignant glioma (abstract). Neurooncol 2005;7:369.9. Stupp R., Hegi M.E., Gilbert M.R. et al. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007;25:4127–36.Stupp R., Hegi M.E., Gilbert M.R. et al. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007;25:4127–36.10. Vredenburgh J.J., Desjardins A., Herndon J.E. 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722–9.Vredenburgh J.J., Desjardins A., Herndon J.E. 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722–9.11. Wagner S.A., Desjardins A., Reardon D.A. et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas (abstract). J Clin Oncol 2008;26:2021.Wagner S.A., Desjardins A., Reardon D.A. et al. Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas (abstract). J Clin Oncol 2008;26:2021.12. Vredenburgh J.J., Desjardins A., Herndon J.E. 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253–9.Vredenburgh J.J., Desjardins A., Herndon J.E. 2nd et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253–9.13. Yung W.K., Albright R.E., Olson J. et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588–93.Yung W.K., Albright R.E., Olson J. et al. A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588–93.